first edition (1980) of the Orange Book - FDA Law Blog

More documents

Recommendations

Info

APPROVED PRESCRIPTION DRUG PRODUCTSDRUG PRODUCT LIST22CARISOPRODOLCAPSULE; ORALSOMAWALLACE LABS/C-W2S0MGTABLET; ORALCARISOPRODOLAA BOLAR PHARM ~AA CHELSEA LABS !50MGAA PHARMADYNE LABS !50MGRELAAA SCHERING !50MG~AA WALLACE LABS/C-W 350MGCARISOPRODOL; *MULTIPLE*SEE CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE; PHENACETINSEE CAFFEINE; CARISOPRODOL; PHENACETINCARMUSTINEINJECTABLE; INJECTIONBICNUBRISTOL LABS/BMCAROTENE! BETACAPSULE; ORALSOLATENEHOFFMANN-LA ROCHECARPHENAZINE MA.LEATECONCENTRATE; ORALPROKETAZINEWYETH LABS/AMHOTABLET; ORALPROKETAZINEWYETH LABS/AMHOlOOMG/VIAL30MGSOMG/ML12.SMG * 25MG * SOMGCEFACLOR MONOHYDRATECAPSULE; ORALCECLORELI LILLYEQ 2S0MG BASE * EQ SOOMG BASEPOWDER FOR RECONSTITUTION; ORALCECLORELI LILLY EQ 12SMG BASE/SML *EQ 2S0MG BASE/SMLCEFADROXIL MONOHYDRATECAPSULE; ORALDURICEFMEAD JOHNSON/BMCEFAMANDOLE NAFATEINJECTABLE; INJECTIONMANDOLELI LILLYCEFAZOLIN SODIUMINJECTABLE; INJECTIONAHCEFAP SKF LABSAPAPAPAPAPKEFZOLELI LILLYCEFOXITIN SODIUMINJECTABLE; INJECTIONMEFOXINMERCK SHARP & DOHME2S0MG * SOOMGEQ SOOMG BASE/VIAL *EQ 16M BASE/VIAL * EQ 2GM BASE/vIALEQ 250MG BASE/VrAL MEg 500MG BASE/VrAL MEg IGM BASE/VrAL M Eg lOSM BASE/VIALEQ S6M BASE/VIALEg 250MG BASE/VIAL MEg 500MG BASE/VrAL MEg IGM BASE/VIAL M Eg 10SM BASE/VrALEQ IGM BASE/VIAL * EQ 2GM BASE/VIAL
j./APPROVED PRESCRIPTION DRUG PRODUCTSDRUG PRODUCT LIST23CEPHALEXIN MONOHYDRATECAPSULE; ORALCEPHALEXrH MONOHYDRATEAB FEDERAL PHARMACAL EQ 2S0HG BASE M EQ SOOHG BASEAB ZENITH LABS EQ 2S0MG BASE M Eg SOOMG BASEKEFLEXAB ELI LILLY EQ 2S0MG BASE M EQ SOOMG BASEPOWDER FOR RECONSTITUTION; ORALKEF LEXELI LILLY EQ 12SMG BASE/SML EQ 2S0MG BASE/SML * EQ IOOMG BASE/MLTABLET; ORALKEF LEX .ELI LILLYCEPHALOGLYCINCAPSULE; ORALKAFOCINELI LILLYCEPHALORIDINEINJECTABLE; INJECTIONLORIDINEELI LILLYCEPHALOTHIN SODIUMINJECTABLE; INJECTIONKEF LINELI LILLYCEPHAPIRIN SqDIUMINJECTABLE; INJECTIONCEFADYLBRISTOL LABS/BMIGM2S0MGSOOMG/VIAL * IGM/VIALEQ IGM BASE/VIAL *EQ 2GM BASE/VIAL *EQ 4GM BASE/VIAL * EQ 20GM BASE/VIALEQ SOOMG BASE/VIAL *EQ IGM BASE/VIAL *EQ 2GM BASE/VIAL *EQ 4GM BASE/VIAL * EQ 20GM BASEIVIALABABCEPHRADINECAPSULE; ORALAHSPORSKF LABSVELOSEFERSANA/PR/SQUIBBINJECTABLE; INJECTIONVELOSEFER SQUIBB AND SONS2S0MG M 500HG250MG M 500MG2S0MG/VIAL * SOOMG/VIAL * IGM/VIAL *2GM/VIAL * 4GM/VIALPOWDER FOR RECONSTITUTION; ORALAHSPORAB SKF LABS l25MG~SML M 2S0HG/5MLVELOSEFAB ERSANA/PR/SQUIBB l25HG~5ML M 250MG/5MLTABLET; ORALVELOSEFER SQUIBB AND SONSCHLOPHEDIANOL HYDROCHLORIDESYRUP; ORALULORIKER LABS/3MCHLORAMBUCILTABLET; ORALLEUKERANBURROUGHS WELLCOMECHLORAMPHENICOLCAPSULE; ORALA!1PHrCOLAB MK LABSCHLORAHPHENrCOLAB ZENITH LABSCHLOROMYCETrHAB PARKE-DAVIS/W-LIGM2SMG/SML2MGlOOMG M 250MG250MGlOOMG M 250MG
Page 5: RXD AND DRUG ACMINISTRATIONAPProVED
Page 9: approved application, a list of app
Page 12 and 13: products that have been approved" i
Page 14 and 15: To assist the user in relating the
Page 16 and 17: an evaluatien of therapeutic equiva
Page 18 and 19: ioavailability data is required for
Page 20 and 21: B - Drug products that FDA does not
Page 22 and 23: and the rate of absorption.pharmace
Page 24 and 25: 4. Erythromycin stearate Tablets -
Page 27 and 28: II. LISTINGSA. FORMAT GUIDEThis p..
Page 29 and 30: CURRENT STATUS - POSSIBLY EFFECTIVE
Page 31 and 32: DRUG ProDUCT EKAMPLESSingle Ingredi
Page 33 and 34: APPROVED PRESCRIPTION DRUG PRODUCTS
Page 53: APPROVED PRESCRIPTION DRUG PRODUCTS
Page 65 and 66: -,----APPROVED PRESCRIPTION DRUG PR
Page 67 and 68: APPROVED PRESCRI~TIOHDRUG PRODUCTSD
Page 77 and 78: DIMENHYDlHNATEAPPROVED PRESCRIPTION
Page 81 and 82: ------"".,APPROVED PRESCRIPTION DRU
Page 91 and 92: APPROVED ¥RESCRIPTION DRUG PRODUCT
Page 95 and 96: '''"APPROVED PRESCRIPTION DRUG PROD
Page 97 and 98: ----..//APPROVED PRESCRIPTION DRUG
Page 105 and 106:
APPROVED PRESCRIPTION DRUG PRODUCTS
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
"~''''''-- .APPROVED PRESCRIPTION D
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
PERCORTEN PIVALATE, DESOXYCORTICOST
Page 191 and 192:
Page 193 and 194:
Page 195:
oAPPROVED PRESCRIPTION DRUG PRODUCT
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
APPROVED PRESCRIPTIOH DRUG PRODUCTS
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243:
Page 246 and 247:
PRESCRIPTION DRUG PRODUCTS DEEMED A
Page 248 and 249:
Page 250 and 251:
show all

first edition (1980) of the Orange Book - FDA Law Blog

Create successful ePaper yourself

Delete template?

Save as template?